BEIJING (Reuters) – Researchers plan to launch a clinical trial for an additional dose of a coronavirus vaccine candidate co-developed by China’s CanSino Biologics Inc and a military-backed research unit, the researchers showed. clinical trial registry data.
A single dose of the Ad5-nCoV vaccine candidate, one of the few that China is pursuing, is scheduled for final phase trials in Pakistan and Russia. The candidate has been approved for use in the Chinese military.
Scientists outside the company have expressed concern that the effectiveness of Ad5-nCoV, which uses a common cold virus that many people have contracted to carry genetic traces of the coronavirus, may be limited.
In response, CanSino said earlier this month that there was no evidence that existing immunity against the common cold virus could severely damage Ad5-nCoV’s ability to trigger antibodies to the novel coronavirus, citing the data collected. from a single-dose Phase 2 study.
In July, researchers working on Ad5-nCoV said that a flexible additional dose may be able to deliver a better immune response, based on their previous experience using this method to develop a common Ebola vaccine. based on the cold virus.
The new two-dose Phase 1 study will test the safety of two doses and their ability to generate an immune response, a registration record released Thursday showed. bit.ly/35Zzi4r
The researchers expect to recruit 168 healthy adults to take two doses of Ad5-nCoV for the study, which is expected to begin September 20 in Wuhan, China.
A CanSino representative declined to comment on the retrial.
Reportage by Roxanne Liu and Tony Munroe; Editing by Christopher Cushing